secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001193125-23-015154
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta pauses MGTA-117 Phase 1/2 trial after participant death possibly related to drug
--------------------------------------------------------------------------------

- Latest participant dosed at Cohort 3 level (0.08 mg/kg) experienced Grade 5 SAE: respiratory failure and cardiac arrest leading to death.
- Death deemed possibly related to MGTA-117; reported to FDA as Suspected Unexpected Serious Adverse Reaction (SUSAR).
- Magenta voluntarily paused dosing after consultation with the trial's safety Cohort Review Committee.
- Trial is in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523015154/0001193125-23-015154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523015154/d395574d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-015154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer